bromocriptine has been researched along with Movement Disorders in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (67.86) | 18.7374 |
| 1990's | 7 (25.00) | 18.2507 |
| 2000's | 2 (7.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butler, DE; Coughenour, LL; DeWald, HA; Downs, DA; Heffner, TG; Lustgarten, D; Pugsley, TA; Wise, LD | 1 |
| Hely, MA; Morris, JG; Reid, WG; Trafficante, R | 1 |
| Cenci, MA; Lindgren, HS; Lundblad, M; Ohlin, KE; Rylander, D | 1 |
| Destee, A | 1 |
| Allain, H; Bentue-Ferrer, D; Pape, D; Reymann, JM; Sabouraud, O; van den Driessche, J | 1 |
| Delwaide, PJ; Hurlet, A | 1 |
| Tamminga, CA | 1 |
| Broe, GA; Hely, MA; Margrie, S; Morris, JG; O'Sullivan, DJ; Rail, D; Reid, WG; Williamson, PM | 1 |
| Adena, MA; Broe, GA; Hely, MA; Morris, JG; O'Sullivan, DJ; Reid, WG; Williamson, PM | 1 |
| Catz, T; Inzelberg, R; Kippervasser, S; Korczyn, AD; Nisipeanu, P; Orlov, E; Rabey, JM; Schechtman, E | 1 |
| Burguera, JA; Chacón, J; Forcadell, F; Giménez-Roldán, S; Liaño, H; Tolosa, E | 1 |
| de Yébenes, JG; García-Ruiz, PJ; Sánchez-Pernaute, R | 1 |
| Albayrak, A; Altinörs, N; Benli, S; Calişaneller, T; Caner, H | 1 |
| Barrett, AM; Crucian, GP; Heilman, KM; Schwartz, RL | 1 |
| Parkes, JD | 1 |
| Lander, CM; Lees, A; Stern, G | 1 |
| Battista, AF; Goldstein, M; Miyamoto, T | 1 |
| Durand, JP; Gautier, JC | 1 |
| Bürki, HR; Jaton, AL; Loew, DM; Vigouret, JM; Züger, PE | 1 |
| Barrett, RE; Cote, LJ; Fahn, S; Isgreen, WP; Snider, SR | 1 |
| Bédard, P; Marsden, CD; Parkes, JD | 1 |
| Iivanainen, M; Juntunen, J; Kaste, M; Kruus, S; Ranta, T; Seppälä, M | 1 |
| Dubuis, R | 1 |
| Bédard, PJ; Boucher, R; Di Paolo, T; Falardeau, P | 1 |
| Bouchard, S | 1 |
| Jankovic, J | 1 |
| Morris, JG | 1 |
| Hershey, LA | 1 |
4 review(s) available for bromocriptine and Movement Disorders
| Article | Year |
|---|---|
[Neurologic indications for bromocriptine (in addition to Parkinson's disease)].
Topics: Adult; Bromocriptine; Child; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Dystonia; Dystonia Musculorum Deformans; Female; Humans; Huntington Disease; Male; Movement Disorders; Nervous System Diseases; Parkinson Disease; Shy-Drager Syndrome; Syndrome; Torticollis | 1984 |
Bromocriptine in the treatment of parkinsonism.
Topics: Apomorphine; Bromocriptine; Catecholamines; Drug Interactions; Ergolines; Humans; Kinetics; Motor Activity; Movement Disorders; Parkinson Disease; Piribedil; Receptors, Drug; Stereotyped Behavior | 1979 |
'On-off' phenomenon: description, incidence and management.
Topics: Bromocriptine; Dose-Response Relationship, Drug; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline | 1987 |
Long-term use of dopamine agonists in Parkinson's disease.
Topics: Bromocriptine; Corpus Striatum; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Movement Disorders; Parkinson Disease; Pergolide; Receptors, Dopamine; Time Factors | 1985 |
7 trial(s) available for bromocriptine and Movement Disorders
| Article | Year |
|---|---|
[Neurologic indications for bromocriptine (in addition to Parkinson's disease)].
Topics: Adult; Bromocriptine; Child; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Dystonia; Dystonia Musculorum Deformans; Female; Humans; Huntington Disease; Male; Movement Disorders; Nervous System Diseases; Parkinson Disease; Shy-Drager Syndrome; Syndrome; Torticollis | 1984 |
Bromocriptine and buccolinguofacial dyskineasias in patients with senile dementia. A quantitative study.
Topics: Bromocriptine; Dementia; Face; Female; Humans; Movement Disorders; Placebos | 1980 |
The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Prevalence; Prospective Studies; Severity of Illness Index; Survival Analysis; Treatment Failure | 1994 |
Age at onset: the major determinant of outcome in Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Bromocriptine; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Postural Balance; Treatment Outcome; Tremor | 1995 |
Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Cabergoline; Double-Blind Method; Ergolines; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Placebos; Prospective Studies | 1997 |
[Treatment of parkinsonian syndromes by bromocriptin].
Topics: Aged; Amantadine; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Ergolines; Female; Humans; Hypotension; Levodopa; Male; Movement Disorders; Nausea; Parkinson Disease, Secondary | 1977 |
18 other study(ies) available for bromocriptine and Movement Disorders
| Article | Year |
|---|---|
(5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Apomorphine; Ataxia; Avoidance Learning; Brain; Cebus; Chemical Phenomena; Chemistry; Dopamine; Male; Mice; Motor Activity; Movement Disorders; Pyrazoles; Rats; Rats, Inbred Strains; Receptors, Dopamine; Saimiri | 1986 |
Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Dementia; Disease Progression; Dose-Response Relationship, Drug; Employment; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Mortality; Movement Disorders; Multicenter Studies as Topic; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Time Factors | 2005 |
The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration.
Topics: Analysis of Variance; Animals; Brain Injuries; Bromocriptine; Cell Count; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Routes; Female; Immunohistochemistry; Levodopa; Lipopolysaccharides; Movement Disorders; Oxidopamine; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Time Factors; Tyrosine 3-Monooxygenase | 2007 |
The use of bromocriptine for testing central dopaminergic reactivity.
Topics: Blood Pressure; Brain; Bromocriptine; Drug Resistance; Humans; Levodopa; Movement Disorders; Parkinson Disease; Receptors, Dopamine; Renin | 1980 |
Antipsychotic and antidyskinetic properties of ergot dopamine agonists.
Topics: Bromocriptine; Dyskinesia, Drug-Induced; Ergot Alkaloids; Humans; Movement Disorders; Psychotic Disorders; Receptors, Dopamine | 1980 |
[A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
Topics: Aged; Bromocriptine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Pergolide; Retrospective Studies; Tremor | 1997 |
Akinetic mutism after fourth ventricle choroid plexus papilloma: treatment with a dopamine agonist.
Topics: Adolescent; Bromocriptine; Cerebral Ventricle Neoplasms; Choroid Plexus; Dopamine Agonists; Female; Humans; Movement Disorders; Mutism; Neurosurgical Procedures; Papilloma; Postoperative Complications | 1999 |
Adverse effect of dopamine agonist therapy in a patient with motor-intentional neglect.
Topics: Attention; Brain; Bromocriptine; Cerebral Infarction; Dopamine Agonists; Humans; Male; Middle Aged; Motor Skills; Movement Disorders; Neuropsychological Tests; Videotape Recording | 1999 |
Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
Topics: Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1979 |
Modification of involuntary movements by centrally acting drugs.
Topics: Aminooxyacetic Acid; Animals; Atropine; Bicuculline; Bromocriptine; Dopamine; Haloperidol; Haplorhini; Levodopa; Movement Disorders; Physostigmine; Picrotoxin; Piperazines; Piribedil; Receptors, Drug; Synaptic Transmission; Thalamic Nuclei; Theophylline | 1975 |
Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712.
Topics: Animals; Behavior, Animal; Brain; Bromocriptine; Catecholamines; Chemical Phenomena; Chemistry; Dihydroergotoxine; Electroencephalography; Ergolines; Humans; Locomotion; Male; Mice; Morphine; Movement Disorders; Rabbits; Rats; Receptors, Dopamine; Reserpine; Sleep; Stereotyped Behavior | 1978 |
The role of bromocriptine in the treatment of parkinsonism.
Topics: Aged; Bromocriptine; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1979 |
Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias.
Topics: Aged; Benzimidazoles; Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1978 |
Effect of bromocriptine on dystonic-athetoid dyskinesias in mentally retarded patients.
Topics: Administration, Oral; Adolescent; Adult; Athetosis; Bromocriptine; Double-Blind Method; Drug Evaluation; Dystonia; Female; Humans; Intellectual Disability; Male; Middle Aged; Movement Disorders; Prolactin | 1978 |
Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Bromocriptine; Butyrophenones; Female; Kinetics; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Spiperone; Time Factors | 1986 |
Optimum symptomatic control of Parkinson's disease with dopaminergic therapy.
Topics: Aged; Bromocriptine; Drug Combinations; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
The treatment of Parkinson's disease.
Topics: Aged; Bromocriptine; Carboxy-Lyases; Humans; Levodopa; Movement Disorders; Nausea; Parkinson Disease; Psychoses, Substance-Induced | 1985 |
Controversies in the treatment of Parkinson's disease.
Topics: Bromocriptine; Humans; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1985 |